MA29260B1 - Derives d'oxindole servant d'agonistes du recepteur 5ht4 - Google Patents
Derives d'oxindole servant d'agonistes du recepteur 5ht4Info
- Publication number
- MA29260B1 MA29260B1 MA30153A MA30153A MA29260B1 MA 29260 B1 MA29260 B1 MA 29260B1 MA 30153 A MA30153 A MA 30153A MA 30153 A MA30153 A MA 30153A MA 29260 B1 MA29260 B1 MA 29260B1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- gastric
- dyspepsy
- oeso
- compounds
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title abstract 2
- 150000005623 oxindoles Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000012895 Gastric disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 206010030216 Oesophagitis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000006881 esophagitis Diseases 0.000 abstract 1
- 230000030135 gastric motility Effects 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) OU UN DE LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES OÙ : A, R1, R2, R3, R4 ET R5 SONT DÉCRITS DANS LA DESCRIPTION, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, ET DES COMPOSITIONS CONTENANT CES COMPOSÉS AINSI QUE LEUR UTILISATION DANS LE TRAITEMENT D'UN ÉTAT À MÉDIATION PAR UNE ACTIVITÉ DE RÉCEPTEUR 5-HT4 TEL QUE (MAIS DE FAÇON NON RESTRICTIVE) LE REFLUX OESO-GASTRIQUE, LA MALADIE GASTRO-INTESTINALE, LE TROUBLE DE MOTILITÉ GASTRIQUE, LA DYSPEPSIE NON ULCÉREUSE, LA DYSPEPSIE FONCTIONNELLE, LE SYNDROME DU CÔLON IRRITABLE (IBS), LA CONSTIPATION, LA DYSPEPSIE, L'OESOPHAGITE, LA MALADIE OESO-GASTRIQUE, LA NAUSÉE, LA MALADIE DU SYSTÈME NERVEUX CENTRAL, LA MALADIE D'ALZHEIMER, LE TROUBLE COGNITIF, LE VOMISSEMENT, LA MIGRAINE, LE TROUBLE NEUROLOGIQUE, LA DOULEUR, LES TROUBLES CARDIOVASCULAIRES, L'INSUFFISANCE CARDIAQUE, L'ARYTHMIE, LE DIABÈTE ET LE SYNDROME D'APNÉE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65527605P | 2005-02-22 | 2005-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29260B1 true MA29260B1 (fr) | 2008-02-01 |
Family
ID=36579484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30153A MA29260B1 (fr) | 2005-02-22 | 2007-08-22 | Derives d'oxindole servant d'agonistes du recepteur 5ht4 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7589109B2 (fr) |
| EP (1) | EP1856110B1 (fr) |
| JP (1) | JP4130220B1 (fr) |
| KR (1) | KR100908547B1 (fr) |
| CN (1) | CN101522668B (fr) |
| AP (1) | AP2007004067A0 (fr) |
| AR (1) | AR053548A1 (fr) |
| AT (1) | ATE513827T1 (fr) |
| AU (1) | AU2006217534B8 (fr) |
| BR (1) | BRPI0607456A2 (fr) |
| CA (1) | CA2598536C (fr) |
| DK (1) | DK1856110T3 (fr) |
| DO (1) | DOP2006000046A (fr) |
| EA (1) | EA012615B1 (fr) |
| ES (1) | ES2366375T3 (fr) |
| GE (1) | GEP20094727B (fr) |
| GT (1) | GT200600083A (fr) |
| HN (1) | HN2006007884A (fr) |
| IL (1) | IL184505A0 (fr) |
| MA (1) | MA29260B1 (fr) |
| MX (1) | MX2007010139A (fr) |
| NL (1) | NL1031218C2 (fr) |
| NO (1) | NO20073566L (fr) |
| NZ (1) | NZ556627A (fr) |
| PE (1) | PE20061096A1 (fr) |
| TN (1) | TNSN07319A1 (fr) |
| TW (1) | TW200640915A (fr) |
| UA (1) | UA86301C2 (fr) |
| UY (1) | UY29389A1 (fr) |
| WO (1) | WO2006090279A1 (fr) |
| ZA (1) | ZA200706420B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126999A (en) | 1996-07-24 | 2002-03-10 | Warner Lambert Co | Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain |
| AP2007004067A0 (en) * | 2005-02-22 | 2007-08-31 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| CA2611639A1 (fr) * | 2005-06-29 | 2007-01-04 | Merck & Co., Inc. | 4-fluoro-piperidines antagonistes du canal calcium de type t |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| WO2007086559A1 (fr) * | 2006-01-27 | 2007-08-02 | Ube Industries, Ltd. | Procede de fabrication d'un compose tetrahydropyrane |
| WO2008021422A2 (fr) * | 2006-08-17 | 2008-02-21 | Wyeth | Procédé de préparation de dérivés d'indolin-2-one servant de modulateurs du récepteur de la progestérone |
| WO2009112874A1 (fr) * | 2008-03-10 | 2009-09-17 | Eurodrug Laboratories B.V. | Composition à libération modifiée comprenant de la doxofylline |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| EP2401268B1 (fr) * | 2009-02-27 | 2015-07-29 | RaQualia Pharma Inc | Dérivés d'oxyindole ayant une activité agoniste au récepteur de la motiline |
| JP5649645B2 (ja) * | 2009-05-07 | 2015-01-07 | ユナイテッド セラピューティクス コーポレイション | プロスタサイクリンアナログの固形製剤 |
| WO2011030349A1 (fr) | 2009-09-14 | 2011-03-17 | Suven Life Sciences Limited | Composés de 1,2-dihydro-2-oxoquinoléine comme ligands des récepteurs 5-ht4 |
| JP6023926B2 (ja) * | 2010-02-12 | 2016-11-09 | 株式会社ＡｓｋＡｔ | 認知症治療のための５−ｈｔ４受容体アゴニスト |
| AP3307A (en) * | 2011-09-19 | 2015-06-30 | Suven Life Sciences Ltd | Heteroaryl compounds as 5-HT4 receptor ligands |
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| EP3105219B9 (fr) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2016007727A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1 |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007722A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1 |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| EP3277689B1 (fr) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| ES2906791T3 (es) * | 2016-02-16 | 2022-04-20 | Strongbridge Dublin Ltd | Composiciones farmacéuticas de veldoreotida soluble en agua con escasa solubilidad en condiciones fisiológicas y métodos de producción |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| WO2020047198A1 (fr) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Sels d'un inhibiteur de lsd1 et leurs procédés de préparation |
| CN114105863B (zh) * | 2021-12-07 | 2023-11-28 | 江苏汉拓光学材料有限公司 | 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552408A (en) * | 1987-09-23 | 1996-09-03 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists |
| US5223511A (en) * | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
| GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
| AU1161292A (en) | 1991-01-09 | 1992-08-17 | Smithkline Beecham Plc | Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
| US5955470A (en) * | 1991-06-11 | 1999-09-21 | Merrell Pharmaceuticals, Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| GB9121170D0 (en) | 1991-10-05 | 1991-11-20 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| US5300512A (en) * | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| US5280028A (en) * | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
| US5521193A (en) * | 1992-06-24 | 1996-05-28 | G. D. Searle & Co. | Benzimidazole compounds |
| FR2694292B1 (fr) | 1992-07-29 | 1994-10-21 | Esteve Labor Dr | Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament. |
| NZ257545A (en) * | 1992-11-05 | 1997-01-29 | Smithkline Beecham Plc | Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions |
| TW251287B (fr) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
| GB9312348D0 (en) | 1993-06-16 | 1993-07-28 | Smithkline Beecham Plc | Pharmaceuticals |
| US5534521A (en) * | 1993-06-23 | 1996-07-09 | G. D. Searle & Co. | Benzimidazole compounds |
| CA2134192A1 (fr) | 1993-11-12 | 1995-05-13 | Michael L. Denney | Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique |
| US5399562A (en) * | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
| GB9414139D0 (en) * | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| DE4440675A1 (de) | 1994-11-14 | 1996-05-15 | Basf Ag | Verfahren zur Herstellung von kautschukmodifizierten Formmassen mittels in den Kautschuk eingebauten, bei thermischer Zersetzung Radikale bildenden Gruppen |
| IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| EP1015429B1 (fr) * | 1997-09-09 | 2004-05-12 | Bristol-Myers Squibb Pharma Company | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES ET LEURS DERIVES EN TANT QU'INHIBITEURS DU FACTEUR Xa |
| US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6310059B1 (en) * | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
| US6492375B2 (en) * | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
| AU1707700A (en) | 1998-10-29 | 2000-05-22 | Bristol-Myers Squibb Company | Novel inhibitors of impdh enzyme |
| MXPA02006137A (es) | 1999-12-20 | 2002-12-05 | Neuromed Tech Inc | Bloqueadores del canal de calcio parcialmente saturados. |
| AU2002216314A1 (en) | 2000-10-12 | 2002-04-22 | Scott A Henderson | Heterocyclic angiogenesis inhibitors |
| IL156315A0 (en) * | 2000-12-07 | 2004-01-04 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| DOP2003000703A (es) * | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| ES2427166T3 (es) | 2003-06-23 | 2013-10-29 | Ono Pharmaceutical Co., Ltd. | Compuesto heterocíclico tricíclico novedoso |
| KR100738784B1 (ko) | 2003-09-03 | 2007-07-12 | 화이자 인코포레이티드 | 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론 |
| WO2005123718A2 (fr) * | 2004-06-15 | 2005-12-29 | Pfizer Japan Inc. | Derives de benzimidazolone d'acide carboxylique |
| US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| AP2007004067A0 (en) * | 2005-02-22 | 2007-08-31 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
-
2006
- 2006-02-10 AP AP2007004067A patent/AP2007004067A0/xx unknown
- 2006-02-10 ES ES06710525T patent/ES2366375T3/es not_active Expired - Lifetime
- 2006-02-10 CA CA2598536A patent/CA2598536C/fr not_active Expired - Fee Related
- 2006-02-10 NZ NZ556627A patent/NZ556627A/en not_active IP Right Cessation
- 2006-02-10 KR KR1020077019124A patent/KR100908547B1/ko not_active Expired - Fee Related
- 2006-02-10 BR BRPI0607456-1A patent/BRPI0607456A2/pt not_active IP Right Cessation
- 2006-02-10 MX MX2007010139A patent/MX2007010139A/es active IP Right Grant
- 2006-02-10 DK DK06710525.4T patent/DK1856110T3/da active
- 2006-02-10 EA EA200701552A patent/EA012615B1/ru not_active IP Right Cessation
- 2006-02-10 JP JP2007556683A patent/JP4130220B1/ja not_active Expired - Fee Related
- 2006-02-10 WO PCT/IB2006/000519 patent/WO2006090279A1/fr not_active Ceased
- 2006-02-10 AT AT06710525T patent/ATE513827T1/de not_active IP Right Cessation
- 2006-02-10 CN CN200680005786XA patent/CN101522668B/zh not_active Expired - Fee Related
- 2006-02-10 GE GEAP200610234A patent/GEP20094727B/en unknown
- 2006-02-10 AU AU2006217534A patent/AU2006217534B8/en not_active Ceased
- 2006-02-10 EP EP06710525A patent/EP1856110B1/fr not_active Expired - Lifetime
- 2006-02-20 DO DO2006000046A patent/DOP2006000046A/es unknown
- 2006-02-20 PE PE2006000207A patent/PE20061096A1/es not_active Application Discontinuation
- 2006-02-20 AR ARP060100601A patent/AR053548A1/es unknown
- 2006-02-21 GT GT200600083A patent/GT200600083A/es unknown
- 2006-02-21 TW TW095105776A patent/TW200640915A/zh unknown
- 2006-02-21 HN HN2006007884A patent/HN2006007884A/es unknown
- 2006-02-22 US US11/360,095 patent/US7589109B2/en not_active Expired - Fee Related
- 2006-02-22 UY UY29389A patent/UY29389A1/es not_active Application Discontinuation
- 2006-02-22 NL NL1031218A patent/NL1031218C2/nl not_active IP Right Cessation
- 2006-10-02 UA UAA200709522A patent/UA86301C2/uk unknown
-
2007
- 2007-07-09 IL IL184505A patent/IL184505A0/en unknown
- 2007-07-10 NO NO20073566A patent/NO20073566L/no not_active Application Discontinuation
- 2007-08-01 ZA ZA200706420A patent/ZA200706420B/xx unknown
- 2007-08-21 TN TNP2007000319A patent/TNSN07319A1/fr unknown
- 2007-08-22 MA MA30153A patent/MA29260B1/fr unknown
-
2009
- 2009-06-24 US US12/490,451 patent/US20100173925A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29260B1 (fr) | Derives d'oxindole servant d'agonistes du recepteur 5ht4 | |
| MA28021A1 (fr) | Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4 | |
| UY29421A1 (es) | Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones. | |
| EA200602122A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| JP4091648B2 (ja) | ２−（１ｈ−インドリルスルファニル）−ベンジルアミン誘導体 | |
| ATE449092T1 (de) | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors | |
| ZA200600427B (en) | 1-sulfonylindole derivatives, their preparation and their use as 5-HT6 ligands | |
| ES2202348T3 (es) | Derivados del azabicicloheptano n-substituidos, como por ejemplo neurolepticos. | |
| CZ282054B6 (cs) | 1-/Pyrido/3,4-b/-1,4-oxazin-4-yl/-1H-indoly, meziprodukty a způsob jejich přípravy a jejich použití jako léčiv | |
| CZ287862B6 (en) | N-substituted 3-azabicyclo[3.2.0]heptane derivatives, process of their preparation and use | |
| US20060183902A1 (en) | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | |
| TH76314A (th) | สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด | |
| US7235568B2 (en) | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | |
| TH81015B (th) | อนุพันธ์ออกซิอินโดล | |
| CA2176962C (fr) | Derives d'azabicycloheptane avec substituant sur l'atome d'azote, leur preparation et leur utilisation | |
| TH106943A (th) | สารประกอบเบนซิมิดาโซโลนที่มีแอคทิวิทีต่อต้าน 5-ht4 รีเซพเตอร์ | |
| TH81015A (th) | อนุพันธ์ออกซิอินโดล | |
| CU20070183A7 (es) | Derivados de oxindol |